Resources from the same session
711O - Avelumab + methotrexate to eradicate low-risk gestational trophoblastic tumors in first-line setting: TROPHAMET phase I/II trial
Presenter: Benoit You
Session: Proffered paper session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
LBA28 - ENGOT-en11/GOG-3053/KEYNOTE-B21: A phase III study of pembrolizumab or placebo in combination with adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
Presenter: Toon Van Gorp
Session: Proffered paper session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Q&A
Session: Proffered paper session: Gynaecological cancers
Resources:
Webcast
LBA29 - Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: Results from PRIMA/ENGOT-OV26/GOG-3012
Presenter: Antonio González-Martín
Session: Proffered paper session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
LBA30 - ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)
Presenter: Bradley Monk
Session: Proffered paper session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA29 and LBA30
Presenter: Philipp Harter
Session: Proffered paper session: Gynaecological cancers
Resources:
Slides
Webcast
Q&A
Session: Proffered paper session: Gynaecological cancers
Resources:
Webcast